 |
PDBsum entry 4lud
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Transferase/transferase inhibitor
|
PDB id
|
|
|
|
4lud
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transferase/transferase inhibitor
|
 |
|
Title:
|
 |
Crystal structure of hck in complex with the fluorescent compound skf86002
|
|
Structure:
|
 |
Tyrosine-protein kinase hck. Chain: a, b. Fragment: unp residues 81-526. Synonym: hematopoietic cell kinase, hemopoietic cell kinase, p59- hck/p60-hck, p59hck, p61hck. Engineered: yes. Mutation: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: hck. Expressed in: spodoptera frugiperda. Expression_system_taxid: 7108.
|
|
Resolution:
|
 |
|
2.85Å
|
R-factor:
|
0.215
|
R-free:
|
0.261
|
|
|
Authors:
|
 |
L.J.Parker,A.Tanaka,N.Handa,K.Honda,Y.Tomabechi,M.Shirouzu,S.Yokoyama
|
|
Key ref:
|
 |
L.J.Parker
et al.
(2014).
Kinase crystal identification and ATP-competitive inhibitor screening using the fluorescent ligand SKF86002.
Acta Crystallogr D Biol Crystallogr,
70,
392-404.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
25-Jul-13
|
Release date:
|
12-Feb-14
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P08631
(HCK_HUMAN) -
Tyrosine-protein kinase HCK from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
526 a.a.
422 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
*
PDB and UniProt seqs differ
at 4 residue positions (black
crosses)
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.2.7.10.2
- non-specific protein-tyrosine kinase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
L-tyrosyl-[protein] + ATP = O-phospho-L-tyrosyl-[protein] + ADP + H+
|
 |
 |
 |
 |
 |
L-tyrosyl-[protein]
|
+
|
ATP
|
=
|
O-phospho-L-tyrosyl-[protein]
|
+
|
ADP
|
+
|
H(+)
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Molecule diagrams generated from .mol files obtained from the
KEGG ftp site
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
| |
|
DOI no:
|
Acta Crystallogr D Biol Crystallogr
70:392-404
(2014)
|
|
PubMed id:
|
|
|
|
|
| |
|
Kinase crystal identification and ATP-competitive inhibitor screening using the fluorescent ligand SKF86002.
|
|
L.J.Parker,
S.Taruya,
K.Tsuganezawa,
N.Ogawa,
J.Mikuni,
K.Honda,
Y.Tomabechi,
N.Handa,
M.Shirouzu,
S.Yokoyama,
A.Tanaka.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The small kinase inhibitor SKF86002 lacks intrinsic fluorescence but becomes
fluorescent upon binding to the ATP-binding sites of p38 mitogen-activated
protein kinase (p38α). It was found that co-crystals of this compound with
various kinases were distinguishable by their strong fluorescence. The
co-crystals of SKF86002 with p38α, Pim1, ASK1, HCK and AMPK were fluorescent.
Addition of SKF86002, which binds to the ATP site, to the co-crystallization
solution of HCK promoted protein stability and thus facilitated the production
of crystals that otherwise would not grow in the apo form. It was further
demonstrated that the fluorescence of SKF86002 co-crystals can be applied to
screen for candidate kinase inhibitors. When a compound binds competitively to
the ATP-binding site of a kinase crystallized with SKF86002, it displaces the
fluorescent SKF86002 and the crystal loses its fluorescence. Lower fluorescent
signals were reported after soaking SKF86002-Pim1 and SKF86002-HCK co-crystals
with the inhibitors quercetin, a quinazoline derivative and A-419259.
Determination of the SKF86002-Pim1 and SKF86002-HCK co-crystal structures
confirmed that SKF86002 interacts with the ATP-binding sites of Pim1 and HCK.
The structures of Pim1-SKF86002 crystals soaked with the inhibitors quercetin
and a quinazoline derivative and of HCK-SKF86002 crystals soaked with A-419259
were determined. These structures were virtually identical to the deposited
crystal structures of the same complexes. A KINOMEscan assay revealed that
SKF86002 binds a wide variety of kinases. Thus, for a broad range of kinases,
SKF86002 is useful as a crystal marker, a crystal stabilizer and a marker to
identify ligand co-crystals for structural analysis.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |